Novartis plans to divest its Indian eyecare portfolio to JB Chemicals, adding to the list of MNCs reducing exposure to the Indian market. The move aligns with Novartis' strategy to capitalize on ophthalmic therapy while offering JB Chemicals entry into a growing business segment. Global Big Pharma has been divesting branded generics to Indian companies, while Indian players are diversifying from the US generics market. The deal is expected to be announced soon. The demand for eyecare is increasing due to the ageing population and greater access, driven by the use of tablets and mobile devices.
from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/NXHFfhB
Subscribe to:
Post Comments (Atom)
PM Surya Ghar Muft Bijli Yojana jobs boost! 1 lakh people to be trained to install solar panels in homes
PM Surya Ghar Muft Bijli Yojana: The ministries of renewable energy and skill development and entrepreneurship have collaboratively develope...
-
A woman, in her early 20s, was stabbed to death by a man in southeast Delhi's Bhogal area on Friday evening, following which the accused...
-
The Delhi High Court on Thursday dismissed the pleas of TTV Dhinakaran and VK Sasikala challenging the Election Commission's order grant...
-
Trading in stock markets this week will be majorly influenced by the upcoming quarterly earnings from IT majors TCS and Infosys, along with...
No comments:
Post a Comment